Literature DB >> 12407678

Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan.

Hsin-Ju Hsieh1, Tony Hsiu-Hsi Chen, Shu-Hui Chang.   

Abstract

Previous research on estimation of the progression of chronic disease, from the normal preclinical screen-detectable phase (PCDP) to the final clinical phase, has usually assumed constant transition rates and has rarely addressed how relevant covariates affect multi-state transitions. The present study proposes two non-homogeneous models using the Weibull distribution and piecewise exponential model, together with covariate functions of the proportional hazard form, to tackle these problems. We illustrate the models by application to a selective breast cancer screening programme. The results of the Weibull model yield estimates of scale and shape parameters for annual preclinical incidence rate as 0.0000058 (SE=0.0000019) and 2.4755 (SE=0.1153), the latter being significantly higher than 1. Annual transition rate was estimated as 0.3153 (SE=0.1385). Relative risks for the effects of late age at first pregnancy (AP) and high body mass index (BMI) on preclinical incidence rate were 1.98 and 2.59, respectively. The corresponding figures on the transition from the PCDP to clinical phase were 1.56 and 1.99, respectively. Non-homogeneous Markov models proposed in this study can be easily applied to rates of progression of chronic disease with increasing or decreasing rates with time and to model the effect of relevant covariates on multi-state transition rates. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12407678     DOI: 10.1002/sim.1277

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  15 in total

Review 1.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Effect of common neuropathologies on progression of late life cognitive impairment.

Authors:  Lei Yu; Patricia A Boyle; Sue Leurgans; Julie A Schneider; Richard J Kryscio; Robert S Wilson; David A Bennett
Journal:  Neurobiol Aging       Date:  2015-04-22       Impact factor: 4.673

3.  Analysis of transtheoretical model of health behavioral changes in a nutrition intervention study--a continuous time Markov chain model with Bayesian approach.

Authors:  Junsheng Ma; Wenyaw Chan; Chu-Lin Tsai; Momiao Xiong; Barbara C Tilley
Journal:  Stat Med       Date:  2015-06-29       Impact factor: 2.373

4.  Multistate models for the natural history of cancer progression.

Authors:  Li C Cheung; Paul S Albert; Shrutikona Das; Richard J Cook
Journal:  Br J Cancer       Date:  2022-07-11       Impact factor: 9.075

5.  Multi-state models and missing covariate data: Expectation-Maximization algorithm for likelihood estimation.

Authors:  Wenjie Lou; Lijie Wan; Erin L Abner; David W Fardo; Hiroko H Dodge; Richard J Kryscio
Journal:  Biostat Epidemiol       Date:  2017-04-04

6.  Estimation of Multi-state Models with Missing Covariate Values Based on Observed Data Likelihood.

Authors:  Wenjie Lou; Erin L Abner; Lijie Wan; David W Fardo; Richard Lipton; Mindy Katz; Richard J Kryscio
Journal:  Commun Stat Theory Methods       Date:  2018-12-29       Impact factor: 0.863

7.  Initiators and promoters for the occurrence of screen-detected breast cancer and the progression to clinically-detected interval breast cancer.

Authors:  Amy Ming-Fang Yen; Wendy Yi-Ying Wu; Laszlo Tabar; Stephen W Duffy; Robert A Smith; Hsiu-Hsi Chen
Journal:  J Epidemiol       Date:  2016-11-28       Impact factor: 3.211

8.  Bayesian measurement-error-driven hidden Markov regression model for calibrating the effect of covariates on multistate outcomes: Application to androgenetic alopecia.

Authors:  Amy Ming-Fang Yen; Hsiu-Hsi Chen
Journal:  Stat Med       Date:  2018-05-21       Impact factor: 2.373

9.  Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors.

Authors:  Y-Y Wu; M-F Yen; C-P Yu; H-H Chen
Journal:  Br J Cancer       Date:  2013-05-14       Impact factor: 7.640

10.  Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study.

Authors:  S Taghipour; D Banjevic; A B Miller; N Montgomery; A K S Jardine; B J Harvey
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.